Andrew Stephenson, MD
The paradigm of localized prostate cancer has continued to shift in recent years, especially regarding the utilization of active surveillance and prostate-specific antigen (PSA) screening, according to Andrew Stephenson, MD.
on Genitourinary Cancers, Stephenson, who is director of Urologic Oncology at Cleveland Clinic, shared some of the past and current data demonstrating the benefits of active surveillance for patients with localized prostate cancer and the evolving opinions on PSA screening.
OncLive: Can you provide an overview of your discussion on active surveillance in prostate cancer?
There has been an important paradigm shift in the management of this disease. We appreciate that there are important impacts on quality of life among the treatments that we would typically offer to patients who have localized prostate cancer—that being surgery and radiation therapy. Although there have been important developments involving the techniques of these treatments, the impact on urinary, bowel, and sexual function continues to be experienced by a substantial number of patients treated with these modalities, even when they are performed by clinicians with substantial expertise.
... to read the full story